JW Pharmaceutical Corporation

Equities

A001060

KR7001060003

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
30,400 KRW +2.01% Intraday chart for JW Pharmaceutical Corporation +4.29% -14.49%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CJ Logistics Secures Distribution Deal for JW Pharm's Intravenous Solutions MT
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
South Korean Shares Touch Seven-Month Low on Concerns over US Fed Rate Hikes MT
JW Pharmaceutical Faces Potential Fine of Nearly 30 Billion Won for Alleged Illegal Rebates MT
JW Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Celleron Therapeutics Ltd acquired Argonaut Therapeutics Limited from JW Pharmaceutical Corporation and Oxford Science Enterprises. CI
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
JW Pharmaceutical to Raise $3 Million via Share Sale MT
JW Pharmaceutical Corporation announced that it expects to receive KRW 9.999993492 billion in funding CI
JW Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
JW Pharmaceutical Corporation announced that it has received KRW 398.470716 million in funding CI
JW Pharmaceutical Corporation announced that it expects to receive KRW 398.470716 million in funding CI
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
JW Pharmaceutical Corporation(KOSE:A001060) dropped from KOSPI 200 Index CI
JW Pharmaceutical Corporation announced that it has received KRW 300 million in funding CI
Market Chatter: JW Pharmaceutical Gets German Health Body's Permit for Phase 2a Study of Oral Atopic Dermatitis Drug MT
Market Chatter: South Korean Drugmakers Queue Up for Clearance of COVID-19 Treatments in January MT
JW Pharmaceutical Corporation completed the acquisition of 50% stake in C&C Research Laboratories from Chugai Pharmaceutical Co., Ltd. CI
JW Pharmaceutical Corporation agreed to acquire the remaining 50% stake in C&C Research Laboratories from Chugai Pharmaceutical Co., Ltd.. CI
Simcere and JW Pharmaceutical Announce Collaboration and License Agreement for Anti-Gout Drug Candidate URC-102 in China CI
JW Pharmaceutical Corporation acquired Euvipharm Pharmaceutical Joint-Stock Company. CI
Chart JW Pharmaceutical Corporation
More charts
JW Pharmaceutical Corp is a Korea-based company engaged in the development and manufacture of pharmaceutical products. The Company mainly produces and sells drugs including supplying protein amino acids in blood, blood and fluid substitutes, hyperlipidemia agents, electrolyte additives, angina pectoris agents, rheumatoid arthritis drugs, perfusion fluid, prostatic hypertrophy drugs, hepatic coma drugs, and iron injections, among others. The Company also researches and develops anticancer drugs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
30,400 KRW
Average target price
41,667 KRW
Spread / Average Target
+37.06%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A001060 Stock
  4. News JW Pharmaceutical Corporation
  5. JW Pharmaceutical Faces Potential Fine of Nearly 30 Billion Won for Alleged Illegal Rebates